RhumbLine Advisers
KLRA

RhumbLine Advisers’s Kailera Therapeutics KLRA Stock Holding History

RhumbLine Advisers’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
+58,387
New +$1.28M ﹤0.01% 2165

Other funds holding KLRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

RhumbLine Advisers's KLRA Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 58,387 shares worth $1.29M. The stake represents ﹤0.01% of the portfolio and ranks #2165 among its holdings.

30 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • RhumbLine Advisers held 58,387 shares of Kailera Therapeutics worth $1.29M as of Q2 2026.
  • Kailera Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2165 holding.
  • 30 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.